Heinrich Heine University Düsseldorf, Institute of Virology, Düsseldorf, Germany.
Department of Haematology, Oncology and Clinical Immunology, University Hospital Düsseldorf, Düsseldorf, Germany.
Br J Haematol. 2021 Jun;193(5):941-945. doi: 10.1111/bjh.17461. Epub 2021 May 6.
Little data are available for the expression of immune checkpoint (IC) molecules within myelodysplastic syndrome (MDS). Here, we report increased PD-L1 CD34 CD38 and PD-L1 CD34 CD38 stem cell frequencies within MDS patients compared to stem cell recipients in remission. Additionally, we observed exceedingly similar PD1 and Tim-3 T-cell frequencies between acute myeloid leukaemia (AML) and MDS samples that were elevated compared to patients in remission. Furthermore, we found highly dynamic Tim-3 and PD1 T-cell frequencies within serial samples of relapsing MDS with excess blasts (MDS-EB II) patients, correlating with further disease markers. These findings support the idea of a potential successful implementation of IC inhibitor treatment in suitable MDS patients.
关于骨髓增生异常综合征 (MDS) 中免疫检查点 (IC) 分子的表达，目前数据较少。在此，我们报告与缓解期的干细胞供者相比，MDS 患者的 PD-L1 CD34 CD38 和 PD-L1 CD34 CD38 干细胞频率增加。此外，我们观察到急性髓系白血病 (AML) 和 MDS 样本之间的 PD1 和 Tim-3 T 细胞频率非常相似，与缓解期患者相比，这些频率升高。此外，我们发现复发 MDS 患者（MDS-EB II）的系列样本中存在高度动态的 Tim-3 和 PD1 T 细胞频率，与进一步的疾病标志物相关。这些发现支持在合适的 MDS 患者中成功实施 IC 抑制剂治疗的想法。
